Status:
NOT_YET_RECRUITING
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Lead Sponsor:
Ankara University
Conditions:
Metastatic Renal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsibl...
Eligibility Criteria
Inclusion
- Age \>18
- Progression after at least 2 lines of systemic therapy or existence of a contraindication to systemic therapies
- At least 3 years of life expectancy
- ECOG performance status ≤ 2
- Ability to sign informed consent
Exclusion
- Age\<18
- Not having received any systemic therapies
- History of a secondary malignancy
- ECOG performance status \> 2
- Any contraindication for radionuclide therapy (pregnancy, lactation, organ disfunction, metastatic lesions with a risk of compression
- Previous history of any radionuclide therapies
- Inability to sign informed consent
Key Trial Info
Start Date :
August 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2028
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06959433
Start Date
August 1 2025
End Date
August 1 2028
Last Update
May 6 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.